AstraZeneca puts 'for sale' sign on Wilmington campus; Army docs tell special forces to stop using malaria drug;

@FiercePharma: Still trending on our website: FDA turbocharges Glaxo's bids for new cancer drug uses. Article | Follow @FiercePharma

@CarlyHFierce: Gold-encrusted mooncakes stuffed with shark's fin "out of favor" in China; corruption crackdown has killed demand. More from Reuters | Follow @CarlyHFierce

> AstraZeneca ($AZN) has put another of its soon-to-be-vacant sites up for sale: a campus in Wilmington, DE, which encompasses 58 acres and two buildings totaling more than 350,000 square feet. Report

> Elite U.S. Army units have been told to stop taking a malaria drug, mefloquine, which the FDA linked with neurological disorders in a July alert. Report

> ViroPharma ($VPHM), working with Goldman Sachs on a possible sale via auction, could fetch a premium of up to 50%, analysts now say; Sanofi ($SNY) and Shire ($SHPG) are said to be interested. Report

> Teva Pharmaceutical Industries ($TEVA) shares have been buoyed by prospects for dividend payments, even as the company faces early competition to its multiple sclerosis blockbuster Copaxone. Report

> Transcept Pharmaceuticals ($TSPT) shareholder Retrophin offered to pay $4 per share for the company, which makes the struggling insomnia remedy Intermezzo. Report | More from FierceBiotech

> Jazz Pharmaceuticals ($JAZZ) sued Amneal Pharmaceuticals, accusing the generics maker of stepping on its patent for the narcolepsy drug Xyrem. Report (sub. req.)

> Aesthetic dermatology drugmaker Sinclair IS Pharma posted a 69% increase in profits for the year ended June 30, to $6.87 million. Report

Medical Device News

@FierceMedDev: Doctors may be overusing MRI facilities they own. More from FierceDiagnostics | Follow @FierceMedDev

@DamianFierce: Covidien plots job cuts, plant closures to save $300M. News | Follow @DamianFierce

@MarkHFierce: Agilent will split in two, keeping its growing Dx business under the current name. Press release | Follow @MarkHFierce

@MichaelGFierce: The artificial pancreas combines an insulin pump with a continuous glucose monitor. Who will get one to market first? Feature from FierceDrugDelivery | Follow @MichaelGFierce

> Roche links with Boehringer Ingelheim in companion Dx deal. Story

> GE-commissioned survey blasts neurological disease Dx delays. Item

> Edwards hit with shareholder suit over 'misleading' Sapien claims. Article

> Nanosphere snags $30.2M in stock sale. Report

Biotech News

@FierceBiotech: Popular yesterday from FierceBiomarkers: 12-year study flags new biomarker for high risk of diabetes. Article | Follow @FierceBiotech

@JohnCFierce: Google is making waves in biotech, glad Google Ventures' Krishna Yeshwant is speaking at our Oct. 15 event in Boston. Register here | Follow @JohnCFierce

@EmilyMFierce: ICYMI yesterday: Stem cell therapy protects vision in preclinical retinal disease study. More from FierceBiotech Research | Follow @EmilyMFierce

> Acceleron raises $93M as Celgene, investors rally around another biotech IPO. Report

> BioMarin spike fades as Roche CEO guns down latest takeover rumor. Story

> Wearing biotech hat, hedge fund vet Shkreli shakes the gate at Transcept. More

> Google's biotech plan: Partner with legendary CEO, tackle aging, think outside the cancer box. Article

Vaccines News

> Study links delayed vaccines to increased risk of whooping cough. More

> Unvaccinated clusters bear brunt of bad year for measles in U.S. Story

> Brain cancer vaccine data gives Agenus' stock a boost. Article

> India gives 114 kids the wrong vaccine in polio mix-up. News

> NIH trialing Sanofi H7N9 vaccine with GSK, Novartis adjuvants. Report

> Visterra advances universal flu antibody to cusp of Phase I. Item

Pharma Manufacturing News

@EricPFierce: Bad luck for this Shamrock. FDA clobbers it with a consent decree and permanent injunction. More | Follow @EricPFierce

> Hikma, partner to build $20M plant in Ethiopia. Story

> FDA uncovers big foul-ups at Ranbaxy plant. Article

> Aesica invests $48M in U.K. plant to make diabetes drugs. News

> MIT works on process to manufacture biologics in 24 hours. Item

And Finally... The roots of financial bubbles could be found in particular functions of the human brain. Report